Competition Hots Up For Biocon In $3.6-Billion Neulasta Biosimilar Market
Tablets are arranged for a photograph in Tokyo, Japan. (Photographer: Kiyoshi Ota/Bloomberg)

Competition Hots Up For Biocon In $3.6-Billion Neulasta Biosimilar Market

The U.S. drug regulator has approved the third biosimilar for a key drug to fight infection from chemotherapy. And that may toughen competition for Biocon Ltd. in one of the biggest markets for Ind...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.